Breaking news
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer’s disease (the RADAR trial)
This randomized, double-blind, placebo-controlled phase 2 clinical trial investigated the potential therapeutic value of losartan, an angiotensin II receptor antagonist, in reducing whole brain volume atrophy in patients with mild-to moderate Alzheimer’s disease.









